Special Event
Special Tour: Guangzhou High-Tech Industrial Enterprise Tour
Date & Time: October 28, 14:00 – 18:00
Meeting Point: Lobby of Nansha Garden Hotel
Fee: Free
The Human Cell Lineage Atlas Facility (CLAF)
Led by GIBH, CAS on Guangzhou International Bio-Island and slated for full operation by 2029, CLAF is an open global platform that maps cell lineage dynamics across the human lifespan using automated instrumentation and AI. By capturing seven spatiotemporal single-cell omics modalities and building digital twins of the human body, CLAF empowers academic research, clinical diagnostics, and cellular-precision drug discovery to advance global healthcare and life sciences.
Guangzhou Saliai Stem Cell Science and Technology Co., Ltd.
Founded in 2009 and headquartered on Guangzhou International Bio-Island, Saliai is a nationally leading high-tech enterprise and NEEQ-listed company specializing in stem-cell research, preparation, storage, and new-drug R&D. Led by Dr. Chen Haijia with Academician Su Guohui serving as Chief Scientist, the company has established multiple national and provincial innovation platforms, undertaken over 40 key national and regional scientific research projects, and holds more than 300 authorized patents. Its independently developed Class-1 innovative drug for knee osteoarthritis has entered Phase-II clinical trials, making it Guangdong's first approved clinical stem-cell new drug. As an industry leader, Saliai actively promotes the standardization, international exchange, and high-quality development of the stem-cell industry, earning numerous national and regional honors.
South China New Materials Innovation Park
Initiated by Gaojin Fuheng Group, South China New Materials Innovation Park (Huaxin Park) has earned over 100 national, provincial, and municipal honors since beginning operation in July 2013. Featuring a 220,000-square-meter Phase I facility, the park pioneered a "leading enterprise guidance + cluster incubation + value co-creation" model. It has successfully cultivated 243 high-tech enterprises and 147 specialized, refined, distinctive, and innovative (SRDI) enterprises—including 18 national-level "Little Giants"—while generating an annual output value of approximately RMB 13 billion, tax contributions of RMB 380 million, and over 7,000 jobs.
{{ 'en' == 'cn' ? item.name : item.name_en }}
{{ 'en' == 'cn' ? item.desc : item.desc_en }}
